Please login to the form below

Not currently logged in
Email:
Password:

Sobi wins European approval for oral form of orphan drug Orfadin

Expandstreatment options for rare genetic disease HT-1

Swedish Orphan Biovitrum (Sobi) 

The European Commission has approved an oral suspension formulation of Swedish Orphan Biovitrum's (Sobi) Orfadin (nitisinone).

The orphan drug treats the rare genetic disease Hereditary Tyrosinaemia type-1 (HT-1), a potentially fatal condition that affects infants and children and can result in liver and kidney failure if untreated.

Sobi's chief medical officer Birgitte Volck said: "The European Medicines Agency has called for more child-friendly formulations and the new oral suspension formulation is a demonstration of Sobi's commitment to the needs of the infants and children diagnosed with HT-1 early in life.

"An oral suspension of Orfadin for paediatric use will facilitate accurate dosing for infants and small children, and contribute to improving quality of life for patients and caregivers."

Orfadin works by blocking the breakdown of tyrosine to reduce the amount of toxic by-products in the body that can cause liver failure, renal dysfunction and neurological complications.

The drug was first approved in 2005 in a capsule formulation, in combination with dietary restriction of tyrosine and phenylalanine, to treat HT-1, which just 1,000 persons have been identified as living with today.

Last year sales of Orfadin rose by almost 50% to bring in SEK 547.9m and Sobi plans to launch the drug's new formulation in the second half of this year.

29th June 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...